InMed Pharmaceuticals (INM) Net Income towards Common Stockholders (QoQ) (2021 - 2026)
InMed Pharmaceuticals (INM) Net Income towards Common Stockholders (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.39% |
| Dec 31, 2025 | -17.45% |
| Sep 30, 2025 | -32.18% |
| Jun 30, 2025 | -2,325.58% |
| Mar 31, 2025 | 97.91% |
| Dec 31, 2024 | -53.47% |
| Sep 30, 2024 | 13.09% |
| Jun 30, 2024 | -12.06% |
| Mar 31, 2024 | -16.55% |
| Dec 31, 2023 | 41.73% |
| Sep 30, 2023 | -653.68% |
| Jun 30, 2023 | 83.14% |
| Mar 31, 2023 | 4.84% |
| Dec 31, 2022 | 40.23% |
| Sep 30, 2022 | 55.40% |
| Jun 30, 2022 | -126.43% |
| Mar 31, 2022 | 18.85% |
| Dec 31, 2021 | -44.12% |